Agenus Inc. (NASDAQ:AGEN) does about 3.19M shares in volume on a normal day but saw 2123680 shares change hands in Friday trading. The company now has a market cap of 569.19M USD and an enterprise value of about $550.08M. Its current market price is $3.19, marking a decrease of -1.39% compared to the previous close of $3.24. The 52 week high reached by this stock is $4.78 whilst the lowest price level in 52 weeks is $1.82. The script in recent trading has seen the stock touch a high of $3.43 and a low of $3.22.

Agenus Inc. (AGEN) has a 20-day trading average at $3.71 and the current price is -33.23% off the 52-week high compared with 75.55% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.57 and its 200-day simple moving average is $3.29. If we look at the stock’s price movements over the week, volatility stands at 6.40%, which decreases to 5.38% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 37.55 to suggest the stock is neutral.

3 analysts observing the Agenus Inc. (AGEN) stock have set the 12-month price targets for the company’s shares at between $5.00 and $6.00. The median price target is 42.0% away from the current levels at $5.50.

FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

H.C. Wainwright downgraded its price target at $10-$5.

The current price level is -14.80%, -9.95%, and -2.74% away from its SMA20, SMA50, and SMA200 respectively, with the AGEN price moving above the 50-day SMA on July 24. Agenus Inc. (AGEN) stock is down -14.11% over the week and -23.38% over the past month. Its price is -21.50% year-to-date and 33.12% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$0.31 above consensus estimates by $0.02. The company’s next earnings report is expected on 07/27/2020, with forecasts estimating quarterly EPS at -$0.27 and -$1.05 for whole year. Expected sales for next quarter are $9.01 million, which analysts say will come at $42 million for the current fiscal year and next year at $60.27 million. In addition, estimates put the company’s current quarterly revenue at an average of $9.33 million.

Its 12-month price target is $5.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $6.00.

Outstanding shares total 145.06M with insiders holding 19.71% of the shares and institutional holders owning 41.54% of the company’s common stock. The company has a return on equity of 87.90%. The beta has a value of 1.99. Price to sales ratio is 6.67.

According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in Agenus Inc. (AGEN) to 4,178,433 shares, mirroring a recent increase by 2.09%. SPDR S&P Biotech ETF added 85699.0 shares of Agenus Inc. common stock bringing its total worth to about $16.42 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 0.77 million shares to end up with 4,011,448 shares worth $15.76 million. iShares Russell 2000 ETF cut their holdings by -2.47% in the company over the course of the most recent quarter. It now holds a 1.68% position in Agenus Inc. thanks to 2.85 million shares amounting to $11.19 million.